去纤苷用药说明书！

[Drug name] Defibrotide, Defitelio, defiteli, defibrotide sodium, defibrotide sodium.

[Indications] It is suitable for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), and renal or pulmonary dysfunction after hematopoietic stem cell transplantation (HSCT).

[Usage and Dosage] The recommended dose for adult and pediatric patients is 6.25 mg/kg, given as a 2-hour intravenous infusion every 6 hours. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT (hematopoietic stem cell transplant) preparation protocol. Defibrotide was administered for a minimum of 21 days. If signs and symptoms of hepatic veno-occlusive disease have not resolved after 21 days, continue defibrotide until resolution of hepatic veno-occlusive disease or for a maximum of 60 days. Defibrotide must be diluted prior to infusion. Do not coadminister defibrotide with other intravenous medications at the same time and in the same intravenous line.

[Side Effects] Hypotension, diarrhea, vomiting, nausea, nosebleeds, and allergic reactions.

【Notes】

Bleeding: Defitelio may increase plasmin activity in vitro and may increase the risk of bleeding in patients with VOD after hematopoietic stem cell transplantation (HSCT). Do not initiate Defitelio treatment in patients with active bleeding. Monitor patients for signs of bleeding. If a patient develops symptoms of bleeding, discontinue use and provide treatment until bleeding stops. Concomitant use of defibrotide and systemic anticoagulation or fibrinolytic therapy (not included for routine maintenance or reopening of central venous lines) may increase the risk of bleeding. Discontinue anticoagulants and fibrinolytics before defibrotide therapy and consider delaying the use of defibrotide until the effect of the anticoagulant has diminished.

Hypersensitivity reactions: Less than 2% of patients treated with defibrotide experienced allergic reactions. These reactions include rash, urticaria, and angioedema. One case of an allergic reaction in a patient has been reported. Monitor patients for hypersensitivity reactions, especially those with past exposure. If a severe hypersensitivity reaction occurs, discontinue defibrotide, treat according to standard of care, and monitor until symptoms resolve.

The above is the instructions for defibrinoside. Please use it correctly under the guidance of a doctor.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.